SMAD2 and Alzheimer disease: Induction of AD using ICV-STZ injection resulted in significant cognitive impairment, oxidative stress, defective Aβ clearance, and histopathological abnormalities that may be attributable to the upsurged TGF-β1/p-Smad2/p21 signaling.